ANDA 40233, held by Duramed Pharmaceuticals (Barr). Methotrexate Sodium.
As of Nov 19, 2026, ANDA 40233 (Methotrexate Sodium), held by Duramed Pharmaceuticals (Barr), was first approved by FDA on Jun 17, 1999, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 17, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Discontinued |
| Apr 29, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Oct 23, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Jun 17, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters